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Abstract
Several therapies have been developed for congenital nystagmus (CN) but without placebo-controlled trials. We investigated a
treatment which combined two therapies that had been advocated by several authors and were reported to improve visual acuity
(VA). A placebo treatment was designed to mimic the time, attention, ‘high tech’ apparatus, and the explanation used in the
experimental treatment. To each group, 38 subjects with CN were randomly allocated. Their VA and contrast sensitivity (CS) were
assessed three times before undergoing treatment for 6 weeks and then once more. An improvement in VA occurred, however, this
was not significantly different in the two groups. The improvement in CS was greater in the experimental than in the control
group, but the difference failed to reach significance in most statistical tests. We conclude that putative therapies for CN should
be assumed to be placebos until proven otherwise with randomized controlled trials. © 1998 Elsevier Science Ltd. All rights
reserved.
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1. Introduction
Congenital nystagmus (CN) describes all forms of
nystagmus which are present within the first four
months of life [1]. There are three sub-types of congen-
ital, or early-onset, nystagmus [2]. In sensory defect
nystagmus, CN is associated with a sensory defect in
the visual pathway [2,3]. Albinism is a relatively com-
mon cause of this sensory defect [1,2,4]. A second type
of CN is neurological nystagmus, resulting from a
neurological disease [2]. This is rare, is not included in
most classifications [1], and will not be discussed in the
present paper. The third type of CN occurs in the
absence of known pathological causes and is called
congenital idiopathic nystagmus, or motor nystagmus
[2]. The diagnosis of idiopathic CN is by exclusion, and
therefore depends on the depth of investigation.
CN causes difficulties for two reasons: (1) reduced
visual acuity (VA); and (2) cosmetic disadvantage. It is
the reduction in VA which causes sufferers greatest
problems, and an improvement in VA is their main aim
when seeking treatment [5]. The poor VA imposes
restrictions on people’s lifestyles and few people with
nystagmus are legally permitted to drive in the UK [2].
Usually, the VA is between 6:12 and 6:36 and im-
proves with age [6], but almost invariably remains
below normal. CN is often associated with hyperme-
tropic astigmatism [7]. Approximately one third of pa-
tients have a null zone in eccentric gaze, and many
adopt a compensatory head posture [6]. Approximately
8% have a null zone on convergence [1] and there may
also be a temporal null zone [1].
1.1. Causes of poor 6ision in congenital nystagmus
Whatever the underlying aetiology of the nystagmus,
some of the reduced VA is likely to be attributable to
the constant oscillation of the eyes, with reduced
foveation period1 [9]. Any treatment directed at this
motor element should not just be aimed at reducing the
nystagmus, but also at changing the waveform to one
1 The foveation period occurs when the target of regard is imaged
at or near the fovea and is characteristically associated with a slowing
of eye velocity [8].
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with a longer percentage foveation time per cycle [1,10].
Since CN occurs during the sensitive period, the re-
duced VA resulting from the eye movements will cause
meridional amblyopia [10], which may be compounded
by meridional amblyopia from astigmatism [11]. As the
child ages, the amplitude of nystagmus usually reduces
[2], so that the reduced vision in older children and
adults may be attributable in part to the ocular oscilla-
tion and in part to amblyopia [13,14] reviewed by [5].
Spierer [15] even believed that, in children outside the
sensitive period, this amblyopia was the major reason
for poor vision in CN. It therefore seems conceivable
that people with CN might benefit from amblyopia
treatment as well as interventions aimed at remediating
the ocular oscillations.
1.2. Attempts to treat congenital nystagmus
Careful refraction and appropriate correction is im-
portant [2,16]. Contact lenses often bring about a small
additional improvement in visual performance [17],
probably due to enhanced feedback through the lid
sensation [18]. Surgical techniques can be successful
[19], however, they are only appropriate in some cases
[6]. One surgical procedure allows the patient to fixate
in their null position without adopting an anomalous
head posture [2]. A similar approach can be taken, for
eccentric null zones, with yoked prisms and, for conver-
gent null zones, with base out prisms or negative lenses
[20,21].
Auditory biofeedback [21–26] and visual biofeed-
back [27] have been used to treat CN, however, there
have been no randomized double-masked placebo-con-
trolled trials (RCTs).
When presented with an after-image, most people
with CN report that the after-image oscillates. This
oscillation is in time with the nystagmus [28], but of
lesser amplitude [29]. This ‘after-image feedback’ (AIF)
has been used in treatment regimens, first by Goldmann
(cited by Stohler [30]) and subsequently by others
[21,30,31], but there have been no RCTs.
There have been a few attempts to treat nystagmus
with therapies designed to treat amblyopia [32,33], but
no RCTs. Mallett developed an instrument for active
[55] amblyopia therapy [33] which he also found to be
effective for treating CN [16]. This instrument uses
intermittent photic stimulation (IPS) whilst the patient
carries out detailed visual tasks using specially designed
targets. The targets are dots, stripes, numbers, and
letters on transparent plates which are back-illuminated
with a red light flashing at 4 Hz [33]. IPS therapy for
CN has been recommended by some authors [34,35]
and has been used in open trials and case studies
[16,21,35].
More recently, the Mallett treatment regimen was
modified to include visual feedback by creating a para-
foveal after-image. Patients attempt to reduce the oscil-
lation of the after-image whilst viewing the IPS unit.
The treatment usually takes place at weekly sessions of
40 min and continues until there have been no fur-
ther improvement in VA for six weeks. An unpublished
open trial suggested that the combined IPS and AIF
treatment was an improvement on the original IPS
treatment [36].
Although the results of the case studies and open
trials described above have been encouraging, these
studies have not been controlled for several potential
confounding variables, i.e. placebo, Hawthorne, and
chart-learning:practice effects. RCTs are especially im-
portant in CN because the nystagmus and VA often
worsen when patients are under stress [2] or when they
are trying to see more clearly [16]. Hence, on subse-
quent visual assessments, patients might be expected to
improve simply through becoming more relaxed about
having their vision assessed.
The aim of the present study was to carry out an
RCT of the use of IPS and AIF to treat CN. Specifi-
cally, we sought to investigate the claims of Mallett [16]
who treated patients aged seven and over with CN.
Like Mallett [36], we included patients with sensory
defect nystagmus resulting from albinism. Mallett [16]
found that ‘‘the major beneficial effect has been to
improve the visual acuity’’, and this was the key vari-
able investigated. We believe that this is the first RCT
of a therapy for CN.
2. Methods
2.1. Subjects
Subjects (Ss) were found through publicity by the
Nystagmus Network, a charitable organisation. The
publicity, explanatory literature, and descriptions to
patients stated that the purpose of the study was to
compare two putative therapies for CN. All Ss who met
the following selection criteria were entered in the
study:
1. No personal history of epilepsy (to avoid the slight
risk of IPS inducing a fit [33].
2. No knowledge of IPS that would allow them to
differentiate the control from the active therapy.
3. Early onset nystagmus [2]. Many Ss were vague
about the age of onset and these Ss were only
included if there was an ophthalmological diagnosis
of CN.
4. The nystagmus must, at some time, have been med-
ically investigated and a pathological cause (other
than oculocutaneous or ocular albinism) excluded.
We wrote to the diagnosing ophthalmologists and
asked them to confirm the diagnosis.
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5. The minimum age was set at 8 years to ensure that
all Ss understood the instructions and were able to
attend to the treatments. Ss, or a parent or
guardian, had to sign an informed consent form (the
study was approved by the Institute of Optometry
Research and Ethical Committee).
6. Ss were required to have had a recent (within the
last year) eye examination at the Institute of Op-
tometry and had to be wearing any appropriate
refractive correction.
Ss were randomly allocated to a group receiving the
experimental treatment and a group receiving the con-
trol treatment. After the first three Ss in each group had
completed the study their results were used in a statisti-
cal power calculation to calculate the number of Ss
required to reject the null hypothesis, if the experimen-
tal therapy was effective2 [37].This gave a target num-
ber of 18 in each group and the final number of Ss was
19 in each group. The mean age of the sample was 24
years and the inter-quartile range was 14–27 years. The
mean ages of the two groups were not significantly
different (t-test, P\0.05).
2.2. Clinical assessments
Ss received a detailed eye examination prior to entry
to the study, including biomicroscopy to detect iris
transillumination. If necessary, refractive corrections
were updated.
2.3. Research 6isual assessments
The data that were used to assess the efficacy of the
treatments were obtained using a battery of tests (re-
search visual assessments) which were administered
four times, three times before treatment and once after
treatment. Repeating the pre-treatment measures estab-
lished intra-subject variability and identified any prac-
tice effects.
The research visual assessments concentrated on the
detailed measurement of VAs, and contrast sensitivity
(CS). We chose to concentrate on assessing any im-
provement in VA since this was our Ss’ main goal and
the relationship between VA and eye movement
parameters in CN may be not be very predictable [12].
We recognised that if we did demonstrate a significant
improvement in VA that future research would be
needed to study eye movements. If the treatment did
not improve VA, then an investigation into its effect on
eye movements would be unwarranted.
All VA and CS measures were carried out with the
patient’s usual refractive correction, and under binocu-
lar conditions. The research visual assessments were
carried out by optometrists (authors: Bruce J.W. Evans,
Janyce Jordahl-Moroz, Mustafa Nabee) who were un-
aware of which treatment Ss had received (Ss were
asked to help maintain this ‘mask’). For all Ss, high
contrast VA was measured first, followed by low con-
trast VA, then CS.
2.3.1. High and low contrast 6isual acuity (VA)
Bailey-Lovie LogMAR charts [38] were used at a
distance of 4.8 m. The logarithmic progression meant
that the viewing distance could be altered to 1.5 m in
cases of very poor VA. The minimum testing distance
was 1.5 m to avoid any significant effect from conver-
gent null zones [39]. Both high contrast charts were
placed side by side so that there were 10 letters on each
line.
A 26 alternative3 forced choice one-up-one-down
staircase procedure [45] was used. The S was directed to
the first letter (on the left) on the top line (largest size)
and asked to name the letter or forced to guess. If
incorrect, then the testing distance was changed to 1.5
m. If correct, then the S was directed to the first letter
on the second line, and so on. When the S made an
error, the examiner moved one step (line) up, to the
next larger size of letter, asking the S to read the first
letter they had not already attempted to read on that
line (in this example, the second letter). This procedure
was repeated, with the S always moving up a line when
wrong and down a line when correct, and always
attempting the first unread letter on the relevant line.
The results were graphed as the testing progressed until
all 10 letters on any one line has been attempted once.
The graph revealed ‘reversals’, which can be character-
ised as peaks and troughs. The first reversal was ig-
nored and the threshold was determined from the mean
of all the other peaks and troughs, except for the last
when there was an odd number of peaks and troughs
[40].
This type of ‘staircase method’ requires the presenta-
tion of fewer stimuli than other methods and is practi-
cally as efficient as maximum likelihood procedures
[41]. Compared with more conventional methods [42],
our method meant that Ss were unlikely to learn the
charts (the two adjacent charts were regularly inter-
changed) and wasted less time reading letters that they
found to be very easy or impossible, but read all the
3 Ten letters, of equal legibility are used in the Bailey-Lovie charts.
However, Ss were unaware of this and are likely to have assumed that
any letters may have been present (their guesses employed the full
alphabet). Hence, it may be appropriate to describe the psychophysi-
cal technique as a 26 alternative forced-choice or, to be precise,
two-interval-26-choice.
2 The power calculation was based on the pre- to post-treatment
improvement in high contrast VA using the formula given by [38],
with the power level set at 90%. From the first six Ss, the minimum
expected difference between the groups in the improvement in VA
was 0.024.
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letters of a size closest to threshold. The method also
had an adaptive element in that more variable Ss would
have read more letters.
The optometrist identified which letter Ss should
attempt by pointing to the side of the line and asking
the patient to read the appropriate letter (e.g. ‘second
letter’). This pointing should have had little effect on
any localization problems resulting from the primarily
horizontal nystagmus.
An identical procedure was used with the Bailey-
Lovie low contrast (10%) charts.
2.3.2. Contrast Sensiti6ity (CS)
Bradley et al. [43] showed that the optimal way to
describe visual function may be to measure high and
low contrast VA and to assess the CS at 4 cycles per
degree (cpd). Therefore, Cambridge Low Contrast
Gratings [44] were used to measure CS at 4 cpd. This
test uses a 2-alternative forced-choice one up four down
algorithm [44,45]. The CS was tested first with the
gratings horizontal and then vertical [11,23,46].
2.4. Questionnaires
To obtain background information and to investigate
Ss’ perceptions of any benefit from treatment, we asked
them to complete pre- and post-treatment question-
naires. These are paraphrased in Tables 1 and 2 and
they used, where appropriate, continuous performance
scales.
2.5. Procedure for the experimental treatment
Both the experimental and the control treatment
were administered by a trained research assistant (au-
thor: Bettine V Evans) who was unaware that one of
Table 2
Post-treatment questionnaire (paraphrased)
1. When viewing objects since you have had the treatment,
have you ever noticed that anything appears to be wob-
bling or moving?
2. If yes how often do you notice objects wobbling or mov-
ing?
3. Compared with before the treatment, how bothersome is
any wobbling or movement that you now experience?
4. What effect has the treatment had on your ability to re-
solve fine detail?
5. If improved, for how long after each treatment session and
at distance or near?
What effect has the treatment had on your general ability6.
to see things in everyday life?
7. If improved, for how long after each treatment session?
8. What effect has the treatment had on any tendency to turn
your head with your nystagmus?
9. If improved, for how long after each treatment session?
10. What effect has the treatment had on your general self-
confidence and ability to live a full life?
11. If improved, for how long after each treatment session?
If only one of the two treatments that we have been inves-12.
tigating turns out to be effective, do you think that it will
be the one that you have been receiving?
13. Do you feel that it would have helped you to continue with
the treatment for longer?
14. If so, how long?
Please list any improvements in the treatment that you have15.
received that you wish to suggest.
the treatments was designed to be an ineffective con-
trol. She was provided with the same explanation as
that given to the Ss (see below). The treatments were
administered in different rooms, so that Ss did not see
the alternative treatment. As recommended by Mallett
[33], both treatments were carried out binocularly, un-
less the patient was monocular (strabismic) when they
were carried out monocularly.
The procedure for the experimental treatment was
the same as that used for the treatment of CN in the
Institute of Optometry clinics, as developed by R.F.J.
Mallett. The only difference for the present research
was that the measurement of VAs, which in the clinic
preceded each treatment session, was omitted.
The IPS unit which was described in detail by Mallett
[33] was used in the present study, and Ss were famil-
iarised with this. They subsequently fixed the centre of
an opaque disc (diameter 1.8 cm) placed centrally in the
screen (53 cm) of a flash gun, into which had been
inserted a UV-blocking filter. The flash gun was held
50 cm from the S and a flash was triggered.
With the room lights dimmed, the S viewed a grey
wall and was asked to observe the after-image. All Ss
reported seeing the after-image oscillating and it was
explained that this corresponded to their ocular oscilla-
tions. The S was then directed to an item of detail (e.g.
a dot, letter or number) on the perspex stimulus plate
of an IPS unit [33]. They were asked to try to minimise
Table 1
Pre-treatment questionnaire (paraphrased)
How old were you when your nystagmus was first detected?
Have you been told of a specific medical condition or eye disease
causing your nystagmus? If yes, what is this condition?
Have you ever been diagnosed as having albinism?
Does anyone in your family have nystagmus? If so, who?
Have you ever been diagnosed as having epilepsy?
Do you experience any significant visual or general discomfort
when exposed to flashing lights?
When viewing objects, does it appear that the object you are
looking at is wobbling or moving? If so, how often?
Have you ever received any type of treatment for nystagmus
before? If so, what was the treatment?
Has anyone told you any details about the nystagmus treatment
being done at the Institute of Optometry? If so, what have you
been told?
Are you able to come to the Institute of Optometry for three one
hour pre-treatment testing sessions, six 40 minute treatment
sessions, and one post-treatment testing session?
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the movement of the after-image whilst trying to make
the detail as clear as possible. Their attention was then
directed to another item of detail and they were in-
structed as above. This was repeated for 5 min, when
the plate was changed for one with smaller detail.
Throughout the treatment session, the plates were made
progressively more detailed until the patient could only
just resolve the detail. The flash was replenished ev-
ery 5 min. The procedure was continued for 6
flashes, or 30–40 min (monocular subjects were treated
for 25 min each eye).
The following explanation was given to Ss: the pur-
pose of the after-image was to help them learn to
reduce their eye movements; the detail on the IPS unit
was designed to stimulate different types of nerve fibre
running from the eye to the brain; the red background
on the IPS unit was designed to help them fixate
centrally; and the flashing of the IPS was designed to
stimulate the eye’s fixation reflex.
2.6. Procedure for the control treatment
The control therapy was designed to mimic the atten-
tion, equipment, and time involved in the experimental
therapy. A full-field (Ganzfeld) after-image was created
and Ss were directed to trace or colour targets over a
rotating grating on a CAM stimulator. The CAM
stimulator is a therapy that was once advocated for
amblyopia [47], but was later shown to be a placebo
[48,49]. In the amblyopia treatment, patients traced on
transparent perspex plates which were placed over ro-
tating square wave gratings. The theory was that the
gratings would stimulate cells in the visual cortex. To
ensure that this type of therapeutic effect did not
inadvertently take place in the present study, the
square-wave gratings were replaced with a 0.5 cpd sine
wave grating. People with CN actually have enhanced
contrast sensitivities to spatial frequencies below 1 cpd
[1], and such spatial frequencies are unrelated to VA.
The details of the procedure are as follows.
The S was familiarised with the CAM unit. The same
flash gun was used as for the experimental treatment.
The Ss chin was placed on the chin rest of a Zeiss bowl
perimeter in a darkened room. The perimeter was
modified so that a circular piece of white card was
placed over the central fixation area. Effectively, the S’s
whole field of view was a uniform white field. The flash
gun was held between the top of the S’s head and the
top of the bowl, facing towards the bowl but behind the
S’s forehead. The flash was triggered.
The S was asked to appreciate the unusual after-im-
age (the effect of this full field, or Ganzfeld, after-image
is peculiar: a large bright area that rapidly disappears).
When they reported that their vision had returned to
normal, their attention was directed to the CAM stimu-
lator and they were instructed to trace or colour in
Fig. 1. Graph of high contrast Bailey-Lovie LogMAR VA at each
research visual assessment (error bars represent 1 S.E.M.).
shapes on the perspex plate. Ss were repeatedly encour-
aged and, after 5 min, the plate was changed for a
different one, as with the IPS unit. The Ganzfeld after-
image was repeated every 5 min, approximately. The
duration of each treatment session was similar to that
for the experimental treatment.
The following explanation was given to Ss: the pur-
pose of the after-image was to ‘‘wipe the visual slate
clean’’ by ‘‘clearing away all previous images’’; the
rotating grating on the CAM unit stimulated the differ-
ent types of nerve fibre running from the eye to the
brain; and the tracing and colouring improved hand-
eye co-ordination and improved eye movement control.
The CAM stimulator is a similar size and shape to the
IPS unit. It was felt that the rotating grating, with
appropriate explanation, was as likely to be associated
with a placebo effect as the flashing red light on the IPS
unit. Ss in both groups appeared to be satisfied by the
explanations.
Fig. 2. Graph of low contrast Bailey-Lovie LogMAR VA at each
research visual assessment (error bars represent 1 S.E.M.).
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Fig. 3. Graph of Cambridge Low Contrast Gratings, in the horizontal
orientation, total score at each research visual assessment (error bars
represent 1 S.E.M.). Contrast sensitivities are given on the right hand
ordinate.
for the horizontal orientation CS all passed the test of
normality (P\0.18) with the exception of the final
assessment (P0.04). All of the distributions for the
vertical CS passed the test of normality (P\0.35).
Therefore, parametric statistics were used, however, the
principal findings were checked and additional analyses
were carried out with non-parametric tests.
Within each group, Meddis’ [50] program of ANOVA
by ranks was used, with Sheffes method of post-hoc
comparison for order effects, to investigate whether the
first three measurements of each variable showed a
significant order effect. They did not (P\0.05), justify-
ing calculating mean pre-treatment values.
Three different statistical approaches were taken,
each of which provided some unique information. First,
for each variable the difference between the mean pre-
treatment value and the post-treatment measure was
calculated. These were not significantly different in the
two groups, for any of the variables (t-test, P\0.20).
For each S, based on the mean and S.D. of his:her three
pre-treatment measures, the z-scores of improvement in
each variable were calculated. The mean z-scores of the
two groups were not significantly different (t-test, P\
0.5) except for the Cambridge gratings vertical orienta-
tion where the experimental group improved by more
than the CAM group (t-test, P0.043). The number of
subjects in each group who improved by two or more
standard deviations was calculated (using their own,
individual, standard deviations). This did not differ
significantly in the two groups (Chi-square, P\0.40),
except for the vertical CS where significantly (Chi-
square, P0.0013) more members of the experimental
group improved by two or more standard deviations.
For the second analysis, a repeated measures
ANOVA was used to compare the mean pre-treatment
measures with the post-treatment results. The S group
was the between-subjects factor (independent variable),
and the effect of treatment on the dependent variable
(VA or CS) was the within-subjects factor. The Bailey-
Lovie high contrast VA was, for all subjects together,
significantly better after the treatment than before
(F(1, 36)13.70, P0.001). However, there was no
significant effect of group (F(1, 36)2.43, P0.13),
nor a significant interaction of (group x treatment)
(F(1, 36)0.02, P0.90). This suggests that the im-
provement in high contrast VA was not significantly
greater in the IPS group, and seems most likely to be
practice:placebo effects. A similar ANOVA for low
contrast VA showed no significant effect of group
(F(1, 36)1.76, P0.19), treatment (F(1, 36)0.73,
P0.40), or interaction of (group x treatment)
(F(1, 36)0. 0.06, P0.81). For the horizontal orien-
tation CS, there was a just significant effect of group
(F(1, 36)4.13, P0.05), but no significant effect of
treatment (F(1, 36)2.90, p0.097), nor interaction of
(group x treatment) (F(1, 36)0.65, P0.43). For the
vertical orientation, there was no significant effect
3. Results
3.1. Research 6isual assessment data
The results are illustrated in Figs. 1–4. An improve-
ment is represented by decreasing LogMAR and in-
creasing CS. Although Figs. 1–4 show that, by chance,
the experimental group had slightly better visual perfor-
mance than the control group; this difference was not
statistically significant for the mean pre-treatment value
for any of the variables (unpaired t-test, P\0.10).
To check whether these data were normally dis-
tributed, frequency distributions were inspected and the
Kolmogorov-Smirnov test was used to compare these
with normal distributions. High and low contrast VA
were clearly normally distributed (P\0.35). The data
Fig. 4. Graph of Cambridge Low Contrast Gratings, in the vertical
orientation, total score at each research visual assessment (error bars
represent 1 S.E.M.). Contrast sensitivities are given on the right hand
ordinate.
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of group, treatment, nor interaction of (group x treat-
ment) (F(1, 36)B2.31, P\0.13).
For the third analysis, a non-parametric analysis of
variance by ranks [50] was used, for each group and
each variable, to determine whether there was a signifi-
cant difference between any of the ranked means of the
four repeated measures. None reached significance at
the P0.05 level. Sheffes method of post-hoc compari-
son was then used to test individual hypotheses for
order effects. The particular hypotheses that were tested
were that (a) the last reading was significantly different
(with VA lower and CS higher) to the first three; (b)
each reading was successively lower:higher (lower for
VA, higher for CS) than the last; (c) the first reading
was significantly lower:higher (higher for VA, lower for
CS) than the others. Only two order effects approached
significance. In the experimental treatment group and
for the horizontal orientation CS the final reading was
significantly better than the first three (P0.044), how-
ever, this was likely to be partly due to an order effect
since each reading tended to be successively better than
the previous one (P0.55). In view of the large num-
ber of statistical tests which were carried out to investi-
gate these order effects, we feel that these marginal
effects are unlikely to be meaningful.
3.2. Indi6idual trends
To determine if there were any particular features of
the Ss whose VA improved most, the following vari-
ables were inspected: age, diagnosis (CN with or with-
out albinism); certainty of diagnosis (based on
information from ophthalmologist); family history; eye
movement characteristics; refractive error; strabismus;
stereopsis; and amblyopia. The eye movement charac-
teristics were obtained, for all subjects, by clinical grad-
ings of the type of movement (pendular or jerk),
direction of eye movements (horizontal, vertical, cir-
cumrotatory), and magnitude of eye movements (clini-
cally graded as 1–5). Independent analysis of eye
movement recordings were obtained for six Ss. No
significant differences between the two groups were
apparent for any of these variables (P\0.05).
3.3. Questionnaire data
A similar proportion of each group (four from exper-
imental and three from the control group) had a diag-
nosis of albinism and six of the experimental and three
of the control group had an immediate family member
with nystagmus. None of the Ss had received any
previous nystagmus treatment, other than refractive
correction.
The data from the final questionnaire showed that
the two groups did not differ significantly (P\0.05) in
any of the variables numbered 2–14 in Table 2. On
average, the duration of any perceived improvements
was described as lasting for more than 3–4 days but
less than all week; but these reports did not differ
significantly in the two groups. It is interesting to note
that subjects in both groups reported a mean improve-
ment in their ability to resolve fine detail of 15%
compared with a mean improvement in high contrast
VA, from first to final assessment, of 7%.
4. Discussion
The claims that we were investigating related to a
heterogeneous group of patients with CN and our
sample reflected this heterogeneity. Indeed, most re-
search studies on putative therapies for CN have not set
selection criteria based on whether the aetiology is
idiopathic, albinotic, or other sensory defect
[16,21,23,25,51].
VA improved a small amount with practice, and
more following interventions that were described as
therapeutic, gave Ss individual attention, and involved
‘high tech’ equipment (Figs. 1 and 2). The improvement
in VA that was associated with the experimental treat-
ment was not significantly different to that associated
with the control treatment.
The findings with CS were less clear-cut. The z-score
analysis suggested that vertical CS increased more in
the experimental group. The non-parametric ANOVA
did not reveal any significant order effect for the verti-
cal orientation, however, it did detect a barely signifi-
cant order effect for the horizontal orientation. The
parametric ANOVA did not reveal any significant in-
teractions of group x treatment.
We attempted, for the experimental group, to corre-
late the z-score of improvement for each of the four
variables with any perceived improvement in the ability
to resolve fine detail and to see in everyday life. Neither
of these questionnaire variables correlated significantly
with any of the z-scores (rsB0.50, P\0.08).
Although the border-line CS findings may be inter-
esting and could be investigated further, the main rea-
son why people in the UK with CN seek treatment is to
pass their driving test [16]. This is dependent on high
contrast VA and the present study suggests that the
improvement in this variable with treatment is most
likely to be attributable to practice and placebo effects.
4.1. Were six treatment sessions enough?
It is possible that we failed to detect a treatment-spe-
cific improvement in the experimental group as the
number of treatment sessions was too few. To investi-
gate this, we studied the records of 25 patients who had
attended the Institute of Optometry clinics for IPS
treatment (with or without after-image feedback) for a
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Fig. 5. Monocular VAs, converted to LogMAR values (vertical axis), as measured immediately prior to each treatment session (horizontal axis)
for the 25 clinic patients who had attended for 13 sessions (gray line) and for the 13 of these who attended for 30 sessions (black line).
prolonged period. Most of these clinical cases, who
were selected randomly, were treated in the 1980s un-
der the supervision of Mr Mallett. The VAs (Snellen
chart or E-chart) that had been recorded before each
treatment session were converted to LogMAR values.
The data for the right eye were used, unless the pa-
tient was strabismic when the better eye was used.
Graphs were plotted of VAs v. treatment session num-
ber for all 25 patients who were treated for 13 sessions
and for the 13 of these patients who were treated for
30 sessions (Fig. 5).
Fig. 5 shows a very marked improvement after the
first treatment, a fairly rapid improvement over the
first five sessions, a slower improvement up to approx-
imately the 12th treatment, and then a plateau. These
findings support the hypothesis of practice:placebo ef-
fects, which were initially marked and then reduced as
they approached the physiological limit of VA. Since
the most rapid improvement occurred over the period
which was investigated in the double-masked trial it
seems likely that there would have been a divergence
of the data for the experimental and control groups if
there had been a genuine treatment effect.
The improvement in VA in the clinical data (Fig. 5)
is similar to that reported in the clinical data from
Mallett [16] and is much greater than that in the
present study (Fig. 1). This is not surprising, since the
standard clinical method of having patients read an
identical chart, letter by letter, before each treatment
session would have enhanced practice and placebo ef-
fects. In contrast, our research protocol and psycho-
physical method were designed to minimize and
control these effects. In addition, the clinical VA
charts lacked the design features of the Bailey-Lovie
charts [38] and viewing distance and testing protocol
may not have been as strictly enforced in the clinic as
in the research.
4.2. Validity of dependent 6ariables
We sought to investigate Mallett’s [16] claim that
‘‘the major beneficial effect has been to improve the
visual acuity’’. An improvement in high contrast VA is
also the main goal of patients seeking treatment. A
detailed analysis of eye movement characteristics is
important to investigate the aetiology of an improve-
ment, however, we felt this would be premature.
An interesting alternative approach was taken by
Sheth et al. [51] who investigated a different putative
therapy for CN. They analysed the eye movement
parameters which most influenced VA and determined
an ‘acuity function’ that, in their small sample, corre-
lated well (r20.90) with VA. They then analysed the
effect treatment had on this function. This approach
was important in their study, which investigated the
instantaneous effect of a treatment. In our study, we
wanted to know the effect of treatment in everyday
life and our psychophysical method of measuring VA
involved repeated measures which would average out
moment-to-moment variations in the nystagmus. Sheth
et al. [51] do not describe their sample, which may
have been selected to have more homogeneous eye
movement characteristics than ours. In any event,
since our aim was to determine whether the treatment
affected VA, even if we had adopted the Sheth et al.
approach and could match their r2 of 90%, this would
have reduced the power of our study to detect change
by 10%.
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4.3. Other treatments: the need for RCTs
Most nystagmus treatments possess characteristics
known to exaggerate a placebo effect [51] and the
relationship between psychological variables, such as
stress, and nystagmus further increases the importance
of controlling for the placebo effect.
If the present study had not been placebo-controlled
and had only compared the experimental group’s first
high contrast VA result with their last, then the study
would have reported a statistically significant improve-
ment (paired t-test, P0.04). However, Fig. 1 shows
that this improvement was mirrored in the control
group. Hence, without the elements of the present study
designed to assess practice and placebo effects, this
research would have reached a completely inappropri-
ate conclusion.
Leung et al. [21], in their open trial of multifaceted
vision therapy for CN, argued that a placebo effect
seemed unlikely as all of their patients had received
previous therapy. This view is not supported by the
literature on the placebo effect [52–54].
5. Conclusions
The data suggest that, although IPS and AIF bring
about an improvement in VA in patients with CN, this
improvement is most likely to be attributable to prac-
tice and placebo effects. Whilst we cannot rule out the
possibility that other measures of visual function might
show an improvement, or that a sub-group of patients
might respond better, this seems unlikely from the
present data. We recommend that putative treatments
for CN should be assumed to be placebos until proved
otherwise with RCTs.
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